Symptomatic treatment of dry eye


The treatment of dry eye syndrome requires an individualized dosage.

Depending on the severity and intensity of the symptoms, instil a drop in the sac, conjunctival 3 to 5 times a day or more frequently if necessary and at bedtime

Take care to administer small drops by gently pressing the unidose and holding it vertically.

Avoid contact of the unidose with the eye and the eyelids.

Consult an ophthalmologist if your dry eye treatment is a long-term or permanent treatment. If the symptoms of dry eye persist or worsen, stop using this medicine and consult your doctor.

Mode of administration

Ophthalmic pathway.

Liquid, whitish, cloudy gel

Pharmacotherapeutic group, Ophthalmic agent, Lacrimal substitute

Code: ATC: S01XA

The carbomer active substance forms a hydrophilic film which adheres to the ocular surface. It binds to water molecules and stabilizes the tear film.

AQUAREST 0.2%, single dose ophthalmic gel has a moderate influence on the ability to drive and use machines within 5 minutes of instillation. A blurred vision, due to the formation of trails for a few minutes, may appear after the instillation of this gel in the conjunctival sac. Accordingly, patients shall not use machinery, operate out of safety conditions and drive vehicles during this period.
Users of contact lenses should remove their front lenses, AQUAREST instillation 0.2%, ophthalmic gel in a container, single dose, and wait 15 minutes before handing over.
< Br>

No known interaction

A, note

If you are using AQUAREST 0.2%, single-dose ophthalmic gel, together with other eye drops, leave an interval of 15 minutes between applications. >
If you are using AQUAREST 0.2%, single-dose ophthalmic gel in conjunction with other ophthalmic ointments, leave an interval of 15 minutes between applications
< Br>
AQUAREST 0.2%, an ophthalmic gel in a single-dose container can prolong the remanence of other eye drops and thus increase their action. In order to avoid this, AQUAREST 0.2%, ophthalmic gel in single-dose container should always be the last; drug to be applied.
Not applicable.

No cases of overdose have been reported.

Any ocular overdose or oral administration that may occur is of no clinical consequence.

Concerning carbomer no data available on fertility. However, the systemic exposure following the use of AQUAREST 0.2%, an ophthalmic gel in unidose container is believed to be low and the effects on fertility are unlikely.
< Br>


For AQUAREST 0.2%, ophthalmic gel in single dose container no clinical data on use during pregnancy is available. The carbomer is probably absorbed only in a small proportion and the systemic exposure is therefore assumed to be low.


No effect on children, breastfeeding is expected due to low systemic exposure to carbomer in women, nursing. AQUAREST 0.2%, ophthalmic gel in a container, unidose may be used during breastfeeding

As a general rule, medicines should not be used during pregnancy or lactation unless a physician has carefully considered all risks and potential benefits. >

Reactions of intolerance to any of the components of this medication may appear very rarely.
As with all ocular preparations, blurred vision may occur shortly after instillation Other reactions such as itching and burning have been observed in studies with comparable products Calcification Of the cornea were very rarely reported when using phosphate-containing eye drops in some patients with significant alterations of the cornea

Reporting of suspected adverse reactions

The reporting of suspected adverse effects after authorization of the drug is important. It provides continuous monitoring of the benefit / risk ratio of the drug. Health professionals report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and network of Regional Pharmacovigilance Centers - website www.ansm.

Symptomatic treatment of dry eye